Pleural effusion and serum soluble fas-ligand levels are elevated in different clinical conditions

Lung

Volumn 180, Issue 1, 2002, Pages 25-32

  Wang, P S ^a   Chen, Y M ^a   Hsieh, Y L ^a   Yu, C F ^a   Tsai, C M ^a   Perng, R P ^a  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

Cirrhosis; Empyema; Fas ligand; Malignant pleural effusion

Indexed keywords

FAS LIGAND;

ADULT; AGED; ARTICLE; BLOOD ANALYSIS; BLOOD LEVEL; CELL COUNT; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; CORRELATION ANALYSIS; DIFFERENTIAL DIAGNOSIS; EFFUSION; EMPYEMA; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; LIVER CIRRHOSIS; LYMPHOCYTE; MAJOR CLINICAL STUDY; MALE; NEUTROPHIL; OUTCOMES RESEARCH; PLEURA EFFUSION; PNEUMONIA; PRIORITY JOURNAL; TUBERCULOUS PLEURISY; VIRUS HEPATITIS;

AGED; APOPTOSIS; BIOLOGICAL MARKERS; DIAGNOSIS, DIFFERENTIAL; FAS LIGAND PROTEIN; FEMALE; HEART FAILURE, CONGESTIVE; HUMANS; LIVER CIRRHOSIS; MALE; MEMBRANE GLYCOPROTEINS; PLEURAL EFFUSION; PLEURAL EFFUSION, MALIGNANT;

EID: 0036903843     PISSN: 03412040     EISSN: None     Source Type: Journal    
DOI: 10.1007/s004080000078     Document Type: Article

References (24)

1. Ashkenazi A, Dixit VM (1999) Apoptosis control by death and decoy receptors. Curr Opinion Cell Biol 11:255-260
2. Chen YM, Whang-Peng J, Chern CH, Kuo BIT, Wang SY, Perng RP (1995) The prognostic value of serum cytokine levels in patients with acute infections. Chin Med J (Taipei) 56:75-79
3. Chouaib S, Asselin-Paturel C, Mami-Chouaib F, Caignard A, Blay JY (1997) The host-tumor immune conflict: From immunosuppression to resistance and destruction. Immunol Today 18:493-497
4. Esser MT, Dinglasan RD, Krishnamurthy B, Gullo CA, Graham MB, Braciale VL (1997) IL-2 induces Fas ligand/Fas (CD95L/CD95) cytotoxicity in CD8+ and CD4+ T lymphocyte clones. J Immunol 158:5612-5618
5. Famularo G, Nucera E, Marcellini S, De Simone C (1999) Fas/Fas ligand on the road: An apoptotic pathway common to AIDS, autoimmunity, lymphoproliferation and transplantation. Med Hypothesis 53:50-62
6. Feldmann G, Lamboley C, Moreau A, Bringuier A (1998) Fas-mediated apoptosis of hepatic cells. Biomed Pharmacother 52:378-385
7. Hanabuchi S, Koyanagi M, Kawasaki A, Shinohara N, Matsuzawa A, Nishimura Y, Kobayashi Y, Yonehara S, Yagita H, Okumura K (1994) Fas and its ligand in a general mechanism of T cell-mediated cytotoxicity. Proc Natl Acad Sci USA 91:4930-4934
8. Hashimoto H, Tanaka M, Suda T, Tomita T, Hayashida K, Takeuchi E, Kaneko M, Takano H, Nagata S, Ochi T (1998) Soluble Fas ligand in the joints of patients with rheumatoid arthritis and osteoarthritis. Arthritis Rheum 41:657-662
9. Haynes NM, Smyth M J, Kershaw MH, Trapani JA, Darcy PK (1999) Fas-ligand-mediated lysis of erbB-2-expressing tumor cells by redirected cytotoxic T lymphocytes. Cancer Immunol Immunother 47:278-286
10. Herrmann JL, Bruckheimer E, McDonnell TJ (1996) Cell death signal transduction and Bcl-2 function. Biochem Society Transact 24:1059-1065
11. Idriss HT, Naismith JH (2000) TNF alpha and the TNF receptor superfamily: Structure-function relationship(s). Microsc Res Tech 50:184-195
12. Ju ST, Matsui K, Ozdemirli M (1999) Molecular and cellular mechanisms regulating T and B cell apoptosis through Fas/FasL interaction. Int Rev Immunol 18:485-513
13. Kanda Y, Chiba S, Tanaka Y, Kami M, Saito T, Izutsu K, Asai T, Yuji K, Ogawa S, Honda H, Mitani K, Usuki K, Urabe A, Shirakawa K, Yatomi T, Nakamura N, Yazaki Y, Hirai H (1999) Increased serum soluble Fas ligand associated with recurrent B-cell non-Hodgkin's lymphoma after autologous peripheral blood stem cell transplantation. Leuk Lymphoma 34:625-628
14. Light RW, MacGregor MI, Luchsinger PC, Ball WC Jr (1972) Pleural effusions: The diagnostic separation of transudates and exudates. Ann Intern Med 77:507-513
15. Mizutani Y, Yoshida O, Bonavida B (1998) Prognostic significance of soluble Fas in the serum of patients with bladder cancer. J Urol 160:571-576
16. Nagata S, Golstein P (1995) The Fas death factor. Science 267:1449-1456
17. Nozawa K, Kayagaki N, Tokano Y, Yagita H, Okumura K, Hasimoto H (1997) Soluble Fas (APO-1, CD95) and soluble Fas ligand in rheumatic diseases. Arthritis Rheum 40:1126-1129
18. Rath PC, Aggarwal BB (1999) TNF-induced signaling in apoptosis. J Clin Immunol 19:350-364
19. Siegel RM, Fleisher TA (1999) The role of Fas and related death receptors in autoimmune and other disease states. J Allergy Clin Immunol 103:729-738
20. Suda T, Takahashi T, Golstein P, Nagata S (1993) Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 75:1169-1178
21. Taieb J, Mathurin P, Poynard T, Gougerot-Pocidalo MA, Chollet-Martin S (1998) Raised plasma soluble Fas and Fas-ligand in alcoholic liver disease. Lancet 351:1930-1931
22. Tanaka M, Suda T, Haze K, Nakamura N, Sato K, Kimura F, Motoyoshi K, Mizuki M, Tagawa S, Ohga S, Hatake K, Drummond AH, Nagata S (1996) Fas ligand in human serum. Nat Med 2:317-322
23. Toyozaki T, Hiroe M, Tanaka M, Nagata S, Ohwada H, Marumo F (1998) Levels of soluble Fas ligand in myocarditis. Am J Cardiol 82:246-248
24. Wu SH, Chu JJ, Chiang CD (2001) Increased soluble Fas ligand concentration in tuberculous pleural effusion. J Formos Med Assoc 100:32-34